ITK and cancer: Their results indicated the effectiveness of 1H-benzo(d)imidazol-2-amine-based inhibitor of interleukin-2-inducible T-cell kinase (ITK) (NCGC00188382, inhibitor #1) to inhibit growth and induce apoptosis in vitro and suppress cancer progression and metastasis in vivo.